Glenmark Pharma discovers new molecule
The company has entered the oncology segment with the discovery of a new molecule.
New Delhi, August 25, 2014: Glenmark Pharmaceuticals has entered the oncology segment with the discovery of a new molecule. The company plans to develop and treat various types of cancers with the recent discovery.
Glenmark Pharmaceuticals SA, a wholly-owned unit of Glenmark, announces the discovery and initiation of studies of a novel clinical development candidate, GBR 1302, the company said in a statement.
GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre Located in La Chaux-de-Founds, Switzerland. It is company’s first clinical candidate targeting oncology indications.
The company is expecting to obtain approval for the initiation of clinical studies for the molecule during the current financial year.